These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
76 related articles for article (PubMed ID: 9386886)
1. Code of marketing practices. Voluntary self-regulation for the Pharmaceutical Manufacturers Association of Canada. Lexchin J Can Fam Physician; 1997 Nov; 43():1997. PubMed ID: 9386886 [No Abstract] [Full Text] [Related]
2. The PMAC code of marketing practices: time for improvement? Pharmaceutical Manufacturers Association of Canada. Desjardins JG CMAJ; 1997 Feb; 156(3):363-4. PubMed ID: 9033417 [TBL] [Abstract][Full Text] [Related]
4. Timeliness of receipt of manufacturers' new product information. Murdoch LA; Lum L Can J Hosp Pharm; 1991 Oct; 44(5):235-8. PubMed ID: 10115576 [TBL] [Abstract][Full Text] [Related]
5. Enforcement of codes governing pharmaceutical promotion: what happens when companies breach advertising guidelines? Lexchin J CMAJ; 1997 Feb; 156(3):351-6. PubMed ID: 9033415 [TBL] [Abstract][Full Text] [Related]
6. The 2002 PhRMA Code and Pharmaceutical Marketing: did anybody bother to ask the reps? Sillup GP; Trombetta B; Klimberg R Health Mark Q; 2010 Oct; 27(4):388-404. PubMed ID: 21058100 [TBL] [Abstract][Full Text] [Related]
7. A better Code of Conduct. Williams R Can Fam Physician; 2005 May; 51():708-9. PubMed ID: 15934276 [No Abstract] [Full Text] [Related]
8. Ethical code of the pharmaceutical industry in Slovakia. (Excerpts). Med Etika Bioet; 2004; 11(3-4):11-22. PubMed ID: 16294449 [No Abstract] [Full Text] [Related]
9. Institution/investigator-initiated clinical trials in Canada. Sedgeworth J; Derewlany L Can J Clin Pharmacol; 2006; 13(2):e236-9. PubMed ID: 16873897 [TBL] [Abstract][Full Text] [Related]
10. Academic drug detailing: an evidence-based alternative. Kondro W CMAJ; 2007 Feb; 176(4):429-31. PubMed ID: 17296946 [No Abstract] [Full Text] [Related]
11. The pharmaceutical industry: a prescription. Woods D Can Med Assoc J; 1983 Oct; 129(7):675. PubMed ID: 6616369 [No Abstract] [Full Text] [Related]
12. Patient awareness and concern regarding pharmaceutical manufacturer interactions with doctors. Edwards D; Ballantyne A Intern Med J; 2009 Mar; 39(3):191-6. PubMed ID: 19383067 [TBL] [Abstract][Full Text] [Related]
14. Pharmaceutical marketing practices: balancing public health and law enforcement interests; moving beyond regulation-through-litigation. Zalesky CD J Health Law; 2006; 39(2):235-64. PubMed ID: 17002233 [TBL] [Abstract][Full Text] [Related]
15. Accreditation program geared to broaden scope of pharmaceutical representatives. Can Hosp; 1970 Jan; 47(1):53. PubMed ID: 5434682 [No Abstract] [Full Text] [Related]
16. On salvaging the pharmaceutical sciences in Canada? Jamali F; Pasutto FM J Pharm Pharm Sci; 1999; 2(2):36-7. PubMed ID: 10952766 [No Abstract] [Full Text] [Related]
17. [Changes in the norms governing practices for the manufacture of pharmaceutical products: implications for the MERCOSUR]. Temprano G; Prats S; Bregni C Boll Chim Farm; 1998 Nov; 137(10):426-38. PubMed ID: 9880947 [TBL] [Abstract][Full Text] [Related]
18. The US drug safety system: role of the pharmaceutical industry. Gibson BR; Suh R; Tilson H Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):110-4. PubMed ID: 17724741 [TBL] [Abstract][Full Text] [Related]
19. Industry-sponsored pharmaceutical trials and research ethics boards: are they cloaked in too much secrecy? Ferris LE CMAJ; 2002 May; 166(10):1279-80. PubMed ID: 12041844 [No Abstract] [Full Text] [Related]
20. Standards for pharmaceutical advertising in Canada. Chepesiuk R CMAJ; 2005 Aug; 173(3):238; author reply 238. PubMed ID: 16076811 [No Abstract] [Full Text] [Related] [Next] [New Search]